Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2024

This Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Acute Bacterial Skin and Skin Structure Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute Bacterial Skin and Skin Structure Infections Understanding

Acute Bacterial Skin and Skin Structure Infections: Overview

A skin and skin structure infection is a bacterial infection of skin and associated tissues. It may be complicated skin and skin structure infection or uncomplicated skin and skin structure infection. Recently, the Food and Drug Administration has called them acute bacterial skin and skin structure infections (ABSSSI). ABSSSI are common and encompass a variety of disease presentations and severity. Increased antimicrobial resistance among both Gram-positive and Gram-negative bacteria with methicillin-resistant Staphylococcus aureus is the main problem in treatment. So, development of newer agents to fight against resistant microbes is the need of the hour.

Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Bacterial Skin and Skin Structure Infections pipeline landscape is provided which includes the disease overview and Acute Bacterial Skin and Skin Structure Infections treatment guidelines. The assessment part of the report embraces, in depth Acute Bacterial Skin and Skin Structure Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Bacterial Skin and Skin Structure Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Acute Bacterial Skin and Skin Structure Infections R&D. The therapies under development are focused on novel approaches to treat/improve Acute Bacterial Skin and Skin Structure Infections.

This segment of the Acute Bacterial Skin and Skin Structure Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Bacterial Skin and Skin Structure Infections Drugs
Lefamulin: Nabriva TherapeuticsLefamulin is the semi-synthetic compound inhibits the synthesis of bacterial protein, which is required for bacteria to grow. It acts by binding to the peptidyl transferase center, or PTC, on the bacterial ribosome in such a way that it interferes with the interaction of protein production at two key sites known as the “A” site and the “P” site, resulting in the inhibition of bacterial proteins and the cessation of bacterial growth. Its binding occurs with high affinity, high specificity and at molecular sites that are different than other antibiotic classes.

Acute Bacterial Skin and Skin Structure Infections: Therapeutic Assessment

This segment of the report provides insights about the Acute Bacterial Skin and Skin Structure Infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Bacterial Skin and Skin Structure Infections

There are approx. 5+ key companies which are developing the therapies for Acute Bacterial Skin and Skin Structure Infections. The companies which have their Acute Bacterial Skin and Skin Structure Infections drug candidates in the most advanced stage, i.e. Phase II include Nabriva Therapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute Bacterial Skin and Skin Structure Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Bacterial Skin and Skin Structure Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Bacterial Skin and Skin Structure Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Bacterial Skin and Skin Structure Infections drugs.

Acute Bacterial Skin and Skin Structure Infections Report Insights

• Acute Bacterial Skin and Skin Structure Infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Bacterial Skin and Skin Structure Infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Bacterial Skin and Skin Structure Infections drugs?
• How many Acute Bacterial Skin and Skin Structure Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Bacterial Skin and Skin Structure Infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Bacterial Skin and Skin Structure Infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Bacterial Skin and Skin Structure Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Nabriva Therapeutics
• TenNor Therapeutics
• Basilea Pharmaceutica

Key Products

• Lefamulin
• TNP 2092
• Ceftobiprole medocaril

Please note: The report will be dispatched within 2-3 days